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Abstract We recently reported the cloning of a new member of 
the serotonin 5-HT2 family, the 5-HT2B receptor. We now 
report the production and characterisation of a specific 
antiserum directed against the C-terminal portion of the mouse 
5-HT2B receptor. After affinity purification, this polyclonal 
antibody recognises specifically the mouse 5-HT2B receptor. 
Immunohistochemical analysis of cryosections from various adult 
mouse tissues reveals a major 5-HT2B receptor expression in 
stomach, intestine and pulmonary smooth muscles as well as in 
myocardium. Furthermore, the antiserum recognises specific 
areas of the mouse brain, including cerebellar Purkinje cells and 
their projection areas. 
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1. Introduction 
Over 95% of the total body serotonin (5-hydroxytrypta- 
mine, 5-HT) is synthesised in the gastrointestinal tract and 
stored in blood platelets, the brain containing only a minor 
proportion. Historically, the discovery of 5-HT in the brain 
shifted the major focus of attention to the central nervous 
system (CNS). However, interest continues to develop con- 
cerning its peripheral action on smooth muscle cells (SMC) 
in particular. Gaddum and Picarelli [1] suggested the presence 
of at least two distinct types of 5-HT receptor in the periph- 
eral organs, since 5-HT contracts guinea pig ileum by (i) a 
direct action on SMC (D type) and (ii) an indirect action 
mediated by release of acetylcholine from parasympathetic 
nerves (M types). The peripheral D type has since been as- 
similated to the 'central 5-HT2 receptor'. 
The wide variety of behavioural and physiological functions 
mediated by 5-HT is reflected in the numerous receptor sub- 
types. These receptors have been classified depending on their 
transduction mechanisms: the 5-HT1 and 5-HT5 subtype as 
adenylyl cyclase inhibitors, 5-HT2 as phospholipase C stimu- 
lators, and 5-HT4, 5-HT6, and 5-HT7 as adenylyl cyclase 
activators, are all members of the G protein-coupled recep- 
tors. The 5-HT3 subtype is a 5-HT gated channel [2]. 
5-HT2 receptors mediate many of the central and peripheral 
physiological functions of 5-HT. Cardiovascular effects in- 
clude contraction of blood vessels and shape change in plate- 
lets; central nervous ystem effects are implicated in obsessive 
compulsive disorders, sleep, learning, memory, anxiety, appe- 
tite, depression, pain, sexual behaviour and mediation of hal- 
lucinogenic effects of lysergic acid diethylamide and related 
hallucinogens. Recently, this family has expanded to include 
5-HT2A, 2B, and 2C subtypes. 
The 5-HT2B receptor subtype is a potential target for ther- 
apeutic compounds, especially for the treatment of migraine 
[3] and cardiovascular diseases, and is active in the CNS (see 
[4] for review of potential action of the 5-HT2B receptor on 
the CNS). At the pharmacological level, the antagonists ritan- 
serin and pizotifen have high affinity for the 5-HT2B receptor 
but are not selective. Some pharmacological properties of an- 
tagonistic ompounds uch as yohimbine relate this pharma- 
cology to that of the 5-HT1B-1D subfamily. The group of T. 
Blackburn reported the synthesis of a first generation of se- 
lective antagonist, the SB200646A compound which possess 
high affinity for 5-HT2B and 5-HT2C but not 5-HT2A nor 
any other receptor tested [5]. This compound acts on hypolo- 
comotion, hypophagia nd anxiogenic paradigms [6]. A sec- 
ond generation of specific antagonists has recently been re- 
ported [7,8]. 
In the mouse, the major sites of expression for 5-HT2B are 
known, by RT-PCR experiment, o be present in adult stom- 
ach, intestine and heart, with detectable xpression also in the 
brain and kidney [9]. In addition, expression of the 5-HT2B 
receptor is observed by in situ hybridisation, from day 8 of 
mouse embryonic development, in the neural fold and in the 
heart rudiment [10], and pharmacologically active during ser- 
otonergic differentiation of the mouse teratocarcinoma de- 
rived 1Cll* cell lines [11]. Similarly, the human 5-HT2B re- 
ceptor is widely expressed in the CNS as well as in the 
periphery [5,12,13]. Transcripts are detected by Northern 
blot in human liver and in lung, heart and kidney mRNA, 
with faint signals in the brain and placenta. Interestingly, we 
have also isolated the human 5-HT2B cDNA from spinal 
cord, foetal brain, aorta, internal mammary artery, placenta, 
neuroblastoma cell line SHSY-5Y, and CSH carcinoid tumour 
cDNA libraries [13]. The rat 5-HT2B receptor expression was 
shown to be restricted to rat stomach fundus [14,15]. How- 
ever, recent reports indicate that this receptor is also expressed 
in rat blood vessels endothelium by pharmacological [16] and 
molecular studies [17]. 
We present here the characterisation f a subtype-specific 
antiserum directed against he 5-HT2B receptor. This antiser- 
um reveals, for the first time, expression of the 5-HT2B re- 
ceptor not only in several mouse peripheral tissues including 
gut and lung SMC, and myocardium, but also in the adult 
brain. 
2. Materials and methods 
*Corresponding author. Fax: (33) 88 65 32 01. 
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2.1. Peptide synthes&, production and characterisation f antibodies 
The peptide sequence was selected from the protein sequence, and 
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corresponds to the C-terminal part of mouse 5-HT2B receptor. The 
sequence has the following 31 amino acid sequence: CSTIQSS- 
SIILLDTLLTENDGDKAEEQVSYI. For immunisation, the peptide 
(2 mg) was coupled through cystein to ovalbumin (10 mg) as a carrier 
protein, using m-maleimidobenzoyl-N-hyroxysuccinimde (MBS) as the 
linking agent [18]. 
Male New Zealand White rabbits were inoculated with ovalbumin 
conjugated peptides following the published procedure [19]. After 
coupling of the peptide with the SulfoLink Coupling Gel (Pierce), 
antibodies were affinity-purified. After serum loading, the column 
was washed and antibodies were eluted with 0. 1 M glycine (pH 2. 
8), and neutralised in the presence of 50 mM Tris-HCl (pH 9. 5). 
After protein quantitation using the Bradford method, the IgG were 
pooled, dialysed against PBS, and stored at -80°C until use. 
2.2. COS cells transfection and immunocytohistochemistry 
Cells were grown in Dulbecco's modified Eagle's medium contain- 
ing 10% foetal calf serum and antibiotics (100 U/ml penicillin; 100 U/ 
ml streptomycin). Cells were transfected for 3 days, using a modified 
calcium-phosphate method [20] with pSG-5 expression vector [21] 
containing the entire coding region of the mouse 5-HT2B receptor 
cDNA. Untransfected cells were used as a control. Cells were fixed 
with 4% paraformaldehyde (PFA) for 20 min at room temperature 
(RT) and permeabilised with 4% PFA containing 0.1% Triton X-100 
and 0.1% NP 40 for 10 min at RT. After overnight incubation with 
primary affinity-purified antibody (1:200), biotinylated anti-rabbit 
antibody (1:200, Vector laboratories) was added for 1 h, followed 
by Avidin-Biotin Complex (ABC; Vector laboratories) for 30 min 
at RT, and revealed by diaminobenzidine (DAB) colour reaction. 
2.3. SDS-PAGE and Western blot analysis 
For Western blot analysis, the membrane fraction was obtained by 
the following procedure: COS-1 transfected cells were homogenised in 
1 ml TC (50 mM Tris-HCl, pH 7. 5, 4 mM CaC12) buffer and cen- 
trifuged for 15 min at 4°C, 12000 rpm. The pellet was resuspended in 
0.5 ml of TC buffer; for tissue membrane fraction, frozen organs were 
homogenised in 10 volumes of 0.25 M sucrose at 4°C and centrifuged 
at 500xg for 10 min. The supernatant was then centrifuged at 
100000×g for 30 min at 4°C. After quantitation by Bradford assay 
(Bio-Rad), the proteins were resolved by 12% SDS-PAGE [22] after 
denaturation with urea sample buffer (0.1 M Tris-HC1, pH 6. 8, 14 M 
urea, 1% SDS, 1% 13-mercaptoethanol, 0.02% bromophenolblue). Pro- 
teins were transferred into nitrocellulose membranes [23]. After block- 
ing in 5% non-fat dry milk in TBST (Tris-buffered saline; 20 mM 
Tris-HCl, pH 7.6, 137 mM NaC1, 0.1% Tween-20) for 2 h at RT 
with agitation, the membranes were incubated with affinity-purified 
antibody (1:500) overnight at 4°C. After incubation with peroxidase- 
conjugated donkey anti-rabbit antibody (1:5000, Jackson Immu- 
noRes. Lab.) for 1 h at RT, visualisation was achieved with the En- 
hanced Chemi-Luminescence (ECL; Amersham) method. 
2.4. 5-HT2B immunoh&tochemistry 
For preparation of frozen sections, 7 week old C57BL/6 mouse 
tissue was incubated in PBS for 20 rain, transferred to plastic wells 
and embedded with OCT compound (Miles, Inc.), except he brain, 
which was first incubated in 2-methyl butane solution on dry ice for 
15 min. All the preparations were stored at -80°C until sectioning. 10 
~tm thick frozen sections were cut on a cryostat, collected on gelati- 
nised slides and kept at -80°C until use. 
For immunohistochemistry, sections were air-dried, fixed with acet- 
one (or 4% PFA) for 10 min at 4°C and transferred into PBST (phos- 
phate-buffered saline and 0.1% Triton X-100). After incubation with 
1% hydrogen peroxide in PBST for 30 min at RT and blocking with 
1.5% NGS (normal goat serum) in PBST for 30 min at RT, the 
affinity-purified primary antibodies diluted 1/200 with PBST contain- 
ing 10% ovalbumin, 1.5% NGS was added for 1 h at RT. For the 
control the same solution was pre-absorbed by addition of 10 gM 
synthetic peptides. After incubation with diluted biotinylated second- 
ary antibody solution (1/200) for 1 h, and with ABC, the immunor- 
eaction product was visualised with DAB or VIP substrate kit (Vector 
laboratories) for 5-10 min. Slides were counterstained with haematox- 
ylin, dehydrated in ethanol, cleared with LMR solution (Labo-Mod- 
erne), cover-slipped with Eukitt (Mounting medium, Labonard), and 
examined with a Zeiss light microscope. 
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Fig. 1. Characterisation f the 5-HT2B receptor antiserum. A: Wes- 
tern blot analysis. Protein extracts from non-transfected (N) Cos-1 
cells and transfected (T) with a 5-HT2B cDNA containing expres- 
sion vector were used for blotting analysis. Panel 1 is the result of 
incubation of the membrane with 5-HT2B-specific antiserum at 1/ 
500, whereas in panel 2 the same serum has been incubated in pres- 
ence of the immunising peptide (10 ~tM), removing the specific 
band. The apparent molecular weight of the protein markers is indi- 
cated on the left and the specific protein band (53.6 kDa) is indi- 
cated by the arrow. The upper band (112 kDa) migrates with an ap- 
parent molecular weight of a dimer and is resistant to treatment by 
tunicamycin, N-glycosidase or alkylating agent (iodoacetamide). 
This band is specific to the 5-HT2B-transfected cells and probably 
represents receptor aggregates due to the high receptor expression 
level in Cos cells since it never appears with protein tissue samples 
(see below). Panel 3 shows the result obtained with protein extracts 
from adult mouse stomach, the soluble fraction (S) and the mem- 
brane fraction (M) after incubation with the 5-HT2B-specific anti- 
serum, revealing one single immunoreactive band of the correct ap- 
parent molecular weight in the membrane fraction, which can be 
blocked by excess of the the immunising peptide (not shown). B: 
Immunocytochemistry of Cos-1 cells. Non-transfected (N) Cos-1 
cells and transfected (T) with a 5-HT2B cDNA containing expres- 
sion vector were used for immunocytochemistry. After fixation in 
4% PFA, the cells were incubated with affinity-purified antibody (1/ 
200), followed by ABC and revealed by DAB colour reaction. Only 
the transfeeted cells present immunoreactive signal. 
3. Results 
3.1. Production and characterisation of  antisera to peptide 
sequence of  the 5-HT2B C-terminus 
Polyclonal antiserum was raised to ovalbumin conjugates of 
the synthetic peptide CST IQSSS I ILLDTLLTENDG-  
KAEEQVSYI .  This sequence corresponds to the C-terminal 
part of the mouse 5-HT2B receptor. The rationale for choos- 
ing this particular sequence was its specificity for this receptor 
subfamily since a screen of the protein data bank does not 
reveal any significant homology to known proteins except the 
human and rat 5-HT2B receptor sequences, scoring 77% and 
83% of homology respectively. The reactivity of the antiserum 
to the peptide sequence was confirmed by immunobinding dot 
assays. We, then, characterised this antiserum using Cos-1 
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Fig. 2. Gastrointestinal distribution of the 5-HT2B receptor. Sections of mouse stomach (A, B) and intestine (C, D) were incubated with 5- 
HT2B antibodies alone (A, C) or in presence of an excess of immunising peptide (B, D) and revealed by VIP staining (A, B) or DAB (C, D), 
and counterstained with haematoxylin. The staining observed over the squamous epithelium in the control is not specific (B). The different 
smooth muscle layers are labelled, the muscularis mucosae (MM), the muscularis externa composed of the inner circular layer (CM) and the 
outer longitudinal layer (LM). All these different smooth muscle cell layers appear to express the 5-HT2B receptor. The original magnification 
is 100× (A, B) and 400× (C, D). 
cells transiently transfected by receptor cDNA-containing 
pSG5 plasmid. Membrane fraction from 5-HT2B transfected 
Cos-1 (not from non-transfected cells or transfected by 5- 
HT1A, 1B, 2A, 2C receptor cDNAs [24]) are specifically rec- 
ognised by this antiserum after immunoblotting (Fig. 1A) and 
revealed a 53 kDa band which fits with the expected 53.6 kDa 
size of the receptor. A higher molecular weight band (112 
kDa) is resistant o treatment by tunicamycin or N-glycosi- 
dase. We therefore have no evidence for N-glycosylation of 
the mouse 5-HT2B receptor and the rat 5-HT2B receptor has 
no consensus sequence for N-glycosylation i its amino-termi- 
nus. This band is specific to the 5-HT2B-transfected cells and 
therefore probably represents receptor aggregates due to the 
high receptor expression level in Cos cells since it never ap- 
pears with protein tissue samples (see below). Fixed 5-HT2B- 
transfected Cos-1 cells (not non-transfected cells) can be spe- 
cifically recognised by the antiserum (Fig. 1B) and immuno- 
reactivity is abolished by antiserum pre-absorption with 
homologous peptide prior to immunocytochemical proce- 
dures. On tissue sample, stomach membrane fraction presents 
a single strong immuno-reactive band of similar size (Fig. 1A- 
3) which can also be blocked by an excess of the immunising 
peptide (not shown). 
The previous analysis of mouse 5-HT2B expression sites 
performed by RT-PCR showed a major site of expression 
for the mRNA in the gastrointestinal tissue [9]. We therefore 
used the 5-HT2B antiserum to refine this information and to 
investigate the exact sites of expression of the 5-HT2B recep- 
tor. 
3.2. The 5-HT2B receptor is expressed in gut SMC 
Immunohistochemistry performed on cryosections stained 
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by VIP or DAB reveals strong specific expression of the re- 
ceptor in external cell layers of the stomach. This corresponds 
to SMC of the stomach and includes the muscularis externa 
with the outer longitudinal (LM) and the inner circular layer 
(CM) as well as the muscularis mucosae (MM) (Fig. 2A,B). 
Similarly, the large intestine xpresses the 5-HT2B receptor in 
longitudinal and circular cell layers which again represents he 
different SMC layers (Fig. 2C,D). Strong expression can also 
be detected in oesophagus, duodenum, and ileum smooth 
muscles (Table 1). 
3.3. The 5-HT2B receptor is expressed in lung and myocardium 
The previous RT-PCR analysis of mouse 5-HT2B mRNA 
showed the other major site of expression in adult and em- 
bryonic lung and heart. When we used the 5-HT2B antiserum 
on sections of the lung region, we observed a strong staining 
of the bronchial SMC (Fig. 3A,B). When staining was per- 
formed on myocardium sections, the immunoreactivity was 
located in striated fibres similar to myocardial fibres, whereas 
the surrounding connective tissue was free from staining (Fig. 
3C,D). Protein extracts from heart or lung tissue cannot be 
evidenced on Western blot probably due to a low expression 
level as suggested by the RNA amount [9]. 
3.4. The 5-HT2B receptor is expressed in the mouse brain 
Expression of the 5-HT2B receptor mRNA was also de- 
tected in the mouse brain [9]. We therefore used the 5- 
HT2B antiserum on mouse brain sections. The strongest ex- 
pression of the 5-HT2B receptor is in cerebellum. Closer ex- 
amination of this expression i dicates that Purkinje cells (Pu), 
granular cell layer (Gc), as well as interpositus cell bodies (Ip) 
are positive (Fig. 4). Therefore, the Purkinje cells, their axonal 
projections through the granular cells to the interpositus nu- 
clei, and the interpositus nuclei (Fig. 4A,C) are positive for 
the receptor. This is in good agreement with the expression of 
the mRNA in the cerebellum, more precisely over the Purkinje 
cell layer seen by in situ hybridisation (unpublished). 
4. Discussion 
One important step in understanding the physiological roles 
of a specific subtype of receptor is a precise knowledge of the 
sites of expression. G-protein-coupled receptors are poorly 
antigenic and therefore their sites of expression are most fre- 
quently deduced from mRNA localisation (in situ hybridisa- 
tion) or binding data on tissue fractions with specific radioli- 
gand. The 5-HT2 subfamily of receptors remain poorly 
understood in terms of expression since specific pharmacolo- 
gical compounds are not yet available for the different sub- 
types. We report here the characterisation f an antiserum 
specific for the 5-HT2B receptor and the localisation of its 
expression. 
We developed a serum against a 5-HT2B-specific peptide 
corresponding to the C-terminus of the mouse 5-HT2B recep- 
tor. This serum appears monospecific to the 5-HT2B receptor 
protein on Western blot analysis in both Cos-transfected cells 
and stomach tissue membrane fraction (Fig. 1) which express 
a high level of 5-HT2B receptor mRNA [9]. When we stained 
sections of mouse tissue, we could reveal immunoreactivity on
different organs and this expression corresponds to the 
mRNA detection (Table 1). 
The 5-HT2B receptor expression is detected in most SMC 
of the gut from oesophagus, duodenum and stomach to intes- 
tine (Fig. 2, Table 1). This expression suggests that 5-HT2B 
receptors may participate in 5-HT-dependent gut contraction. 
The rat fundic strip has been known for a long time to be 
extremely sensitive to 5-HT [25]. However, the receptor which 
mediates the fundic SMC contraction has not been easy to 
characterise pharmacologically. The rat fundus receptor was 
first classified as a 5-HTl-like receptor and later as an orphan 
receptor. Only recently, the new subtype of 5-HT2 receptors, 
5-HT2B, has been cloned from human, mouse and rat species 
[9,13-15]. It has been shown to mediate the contraction of the 
rat stomach fundus [26] and human intestine [27]. Therefore, 
this report confirms the 5-HT2B localisation and the probable 
Table 1 
Localization of serotonin 5-HT2B receptor in mouse 
Organ Tissue distribution Immunoreactivity ~ mRNA level b
Stomach smooth muscle ++++ ++++ 
Oesophagus smooth muscle +++ 9 
Duodenum smooth muscle +++ ? 
Intestine 
small intestine smooth muscle ++ +++ 
large intestine smooth muscle ++++ +++ 
Heart myocardium ++ ++ 
Lung ++ 
bronchiae smooth muscle ++++ ? 
artery smooth muscle +++ ? 
endothelium ++ ? 
Kidney cortex + ++ 
Adrenal gland cortex + ? 
Liver -- -- 
Spleen - - 
Brain + 
cerebellum + + 
Purkinje cell + ? 
granular cell layer ++ ? 
interposed cellular nuclei ++ ? 
cerebrum hippocampus + + 
~Relative immunoreactivity was estimated based on colour intensity of staining. 
bRelative mRNA expresssion level was determined by quantitative RT-PCR [9,34]. 
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Fig. 3. Expression of the 5-HT2B receptor in the lung and heart. Sections of lung (A, B) and of heart (C, D) were incubated with 5-HT2B 
antibodies alone (A, C) or in the presence of an excess of irnmunising peptide (B, D) and revealed by VIP staining, and counterstained with 
haematoxylin. The smooth muscle cell layer surrounding the bronchial epithelium is indicated (SM) as well as the bronchial lumen (Br) and the 
artery lumen (Ar). The staining observed over the secreting epithelium in the control is not specific (B). Finally, muscle fibres of the myocar- 
dium are positively stained whereas the connective tissue is not (C, D). The original magnification is 200 × (A, B) and 400 X (C, D). 
function of the 5-HT2B receptor in serotonin-mediated gut 
contractions. In addition, we detected mouse 5-HT2B receptor 
expression in bronchial SMC (Fig. 3). Bronchial expression of 
the 5-HT2B receptor may correspond to the 5-HT receptor 
implicated in bronchoconstriction, recently described as an- 
tagonistic of histamine action [28] and bronchial asthma 
[29]. The peripheral expression of 5-HT2 receptor subtypes 
is still a matter of controversy. If the 5-HT2C receptor is 
considered to be mainly restricted to the CNS, 5-HT2A re- 
ceptor expression in the periphery has been reported in plate- 
lets, SMC of blood vessels [17,30] and myometrium [31], but 
not gut or lung [32]. Therefore the 5-HT2B receptor may 
represent a major 5-HT2-1ike receptor in SMC. In addition, 
we detected its expression in the cell line DDT-MFI I ,  hamster 
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Fig. 4. Brain expression of the 5-HT2B receptor. Sections of mouse brain were incubated with 5-HT2B antibodies alone (A, C), or in the pres- 
ence of an excess of immunising peptide (B, D) and revealed by DAB staining and counterstained with haematoxylin. The major staining is 
over the cerebellum region where cerebellar nuclei are positively revealed, more precisely the interpositus nucleus, shown by a bracket in A and 
B and at higher magnification i  C and D. The Purkinje cells are stained (Pu), as well as their axonal projecting area in the interpositus nu- 
cleus (Ip) where cell bodies are also revealed. This seems to be correlated by the positive staining observed in the projecting area of the interpo- 
situs nucleus uch as the red nucleus (not shown). The granular cells layer (Gc) is also stained and may correspond to projection from the lat- 
eral reticular nuclei or from dorsospino cerebellar tract innervation. The original magnification is 2 x (A, B) and 400 × (C, D). 
vas deferens leiomyosarcoma, and in both human and Mas- 
tomys carcinoid tumours [24] which are derived from entero- 
chromaffin cells of the gut. 
The cardiovascular expression of the 5-HT2B receptor is 
detected in both the myocardium and the vascular endothe- 
lium (Fig. 3, Table 1). In the heart, function and distribution 
of 5-HT receptors have been shown to be complex and species 
dependent [33]. The presence of 5-HT2B receptors may ex- 
plain partially this species dependence since the pharmacology 
of this receptor subtype shows a very strong species pecificity 
[34]. In the myocardium, the 5-HT2B receptor may be similar 
to the one mediating the positive inotropic response to 5-HT 
in the atria [35]. In blood vessels, this expression may corre- 
spond to the 5-HT endothelial receptor (Fig. 3A) [17,36]. Ser- 
otonergic receptors are known to act in synergy with growth 
factors to mediate SMC contraction and proliferation. SMCs 
regulate gut contraction, blood pressure and participate in 
angiogenesis. The SMC proliferation is involved in coronary 
arterial diseases, hypertension and atherosclerosis, all of 
which are, amongst others, under serotonergic control. The 
contractile response of SMC involves intracellular Ca 2+ re- 
lease under the control of the second messengers IP3 and 
DAG released by phospholipase C and is controlled by phos- 
phorylation of the myosin light chain (MLC) by the MLC 
kinase; its relaxation is induced by phosphatase activation 
regulated by intracellular cGMP and cAMP levels [37]. We 
have recently shown that, in addition to IP3 production, stim- 
ulation of the 5-HT2B receptor is mitogenic via Ras and 
MAP kinase stimulation and transforms the mouse fibroblast 
LMTK-  cells [24]. Therefore, this receptor may be involved in 
MAP kinase stimulation in SMC where it may also be mito- 
genic. Furthermore, nitrogen oxide (NO), a positive effector 
of guanylyl cyclase, is a major vasodilator [38] and seems to 
be released from vascular endothelium [37]. Experiments in- 
dicating that the 5-HT2B receptor also regulates NO synthase 
activity by 5-HT in carcinoid tumour cells may also be related 
to NO functions in blood vessels (unpublished results). 
Although these results have to be refined, the localisation of 
the 5-HT2B receptor in blood vessel endothelium confirms the 
previous pharmacological nd mRNA analysis [17,39]. We 
also detected the human 5-HT2B cDNAs in aortic and inter- 
nal mammary artery libraries and the pharmacology of the 5- 
HT2B receptor correlates with that of the human saphenous 
vein [10]. The 5-HT2B receptor may, therefore, participate in 
the 5-HT endothelial-dependent vasorelaxation which is lost 
when endothelium is damaged [40]. In addition, the 5-HT2B 
receptor may participate in the serotonin-induced contraction 
of the cerebral arteries [41]. 5-HT and 5-HT2B/2C receptor 
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are suspected to play a role in migraine attacks [3,42], a 
pathology which results from abnormal 5-HT-induced vaso- 
constriction of the cerebral arteries. 
Finally, the expression of the 5-HT2B receptor in the brain 
is mainly localised in cerebellar nuclei (Fig. 4). This expression 
may relate the 5-HT2B receptor to motor controls known to 
utilise 5-HT, such as the inhibition of spontaneous locomotor 
behaviour by the 5-HT2B/2C receptor or head twitches, wet- 
dog shakes, and back-muscle contractions by the 5-HT2A/2B 
receptor [43]. These observations may explain the hypoloco- 
motion induced by the 5-HT2B-specific antagonist [6]. 
To conclude, we report for the first time the detailed sites of 
5-HT2B receptor expression, detected by specific antiserum, in 
the cerebellum where it could be involved in motor control, in 
the gut or lung SMC where it probably regulates 5-HT-de- 
pendent contraction, and in heart myocardium where it could 
participate at the inotropic response to 5-HT. This work 
opens new possibilities for investigating the different physio- 
logical functions of 5-HT and to develop specific drugs affect- 
ing these functions. 
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